Melanoma Care Options™: Update on Advances in Melanoma: Current Progress and Future Promise
1. Interested in reading the publication and earning CME credits online? Click here to register, click here to download the publication and click here to take the CME test and evaluation on line.
2. Just want to download the publication? Click here to download the publication. You can always print out and fax the CME information to us later.
Continuing Medical Education Information
To receive a maximum of 1.5 AMA PRA Category 1 Credits™ for this activity:
To receive up to 1.5 CNE credits for this activity:
This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who screen for and/or treat melanoma.
Statement of Need
Metastatic melanoma continues to be a challenging disease to treat. However, recent clinical trials of targeted and immune-based treatments have shown progress and potential for the future. However, practicing clinicians who diagnose and treat melanoma may find it difficult to identify which promising research is truly significant and likely to influence their contemporary practice in the near future. Through expert interpretation of the most current data concerning the pathogenesis, staging, and treatment of melanoma, including discussion of ongoing clinical trials, this program provides participants with a more detailed understanding of key emerging data and how to translate it to a practice setting.
After completing this activity, participants should be able to:
Accreditation and Credit Designation
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Each physician should claim only those credits commensurate with the extent of his or her participation in the activity.
1.5 contact hours of Continuing Nursing Education will be granted by the University of Pittsburgh Medical Center. The University of Pittsburgh Medical Center is an approved provider of continuing nursing education by the Pennsylvania State Nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Centerís Commission on Accreditation.
We gratefully acknowledge an educational grant from Merck in support of this activity
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in this activity.
John M. Kirkwood, MD (Editor)
Professor and Vice Chairman for Clinical Research
Department of Medicine
University of Pittsburgh School of Medicine
Grant/Research Support: Berlex Laboratories, Pfizer, Inc, Schering-Plough Corporation
Speakerís Bureau: Schering-Plough Corporation
Robert H. I. Andtbacka, MD, CM, FRCS(C)
Assistant Professor of Surgery
University of Utah
The Huntsman Cancer Institute
Salt Lake City, UT
No financial relationships to disclose
Sancy A. Leachman, MD, PhD
Director, Melanoma and Cutaneous Oncology Program
Department of Dermatology at the University of Utah
Huntsman Cancer Institute
Salt Lake City, UT
Grant/Research Support: Myriad Genetics
Susan M. Swetter, MD
Professor of Dermatology
Director, Pigmented Lesion & Melanoma Program
Stanford University Medical Center/VA Palo Alto Health Care System
Grant/Research Support: Schering-Plough Corporation
Ahmad A. Tarhini, MD, MSc
Assistant Professor, Department of Medicine
University of Pittsburgh
Grant/Research Support: Bristol Myers Squibb, Novartis, Pfizer Oncology, Schering-Plough Research International
Date of Original Release:March 25, 2010
Expiration date: March 24, 2011
Last Review: March 4, 2010